CD274 and hepatocellular carcinoma: Twenty-two systemic treatment-naïve HCC patients were treated with combination avelumab (anti-PD-L1 therapy) and axitinib (mTKIs) with an ORR of 13.6% and median progression-free survival (mPFS) of 5.5 months (see Table 3) [146].